CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA by Ugo Testa, Elvira Pelosi, Germana Castelli

Get full text

Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy by Charles J. Milrod, Rebecca Steuer, Ari Pelcovits

Get full text

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma by Chengcheng Zhang, Linling Wang, Qianzhen Zhang, Junjie Shen, Xia Huang, Meiling Wang, Yi Huang, Jun Chen, Yanmin Xu, Wenxu Zhao, Yanan Qi, Yunyan Li, Yanjiao Ou, Zhi Yang, Cheng Qian

Subjects: “…chimeric antigen receptor T cells…”
Get full text

Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic by Caitlin R Hopkins, Joseph A Fraietta

Get full text

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma by Hui-Ju Hsieh, Ryan Urak, Mary C. Clark, Larry W. Kwak, Stephen J. Forman, Xiuli Wang

Get full text

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review by Joseph Sassine, Emily A. Siegrist, Roy F. Chemaly

“…In this narrative review, we explore the burden and risk factors of various herpesvirus infections in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies (BsAb) for the treatment of hematologic malignancies. …”
Get full text

Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia by Danni Xie, Bing Wang, Xue Bai, Xin Jin, Wenyi Lu, Meng Zhang, Yi Zhang, Xinping Cao, Mingfeng Zhao, Yuanyuan Ji

Get full text

Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies by Chenyun Zhang, Haizhou Liu

“…In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made groundbreaking progress in the treatment of various cancer types, particularly hematological malignancies. …”
Get full text

Corrigendum: Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma by Chengcheng Zhang, Linling Wang, Qianzhen Zhang, Junjie Shen, Xia Huang, Meiling Wang, Yi Huang, Jun Chen, Yanmin Xu, Wenxu Zhao, Yanan Qi, Yunyan Li, Yanjiao Ou, Zhi Yang, Cheng Qian

Subjects: “…chimeric antigen receptor T cells…”
Get full text

Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis by Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder, Joseph Maakaron, Monalisa Ghosh, David Frame, Ahmed Galal, Justin Tossey, Nausheen Ahmed, Evandro Bezerra, Nathan Denlinger, Marcos de Lima, Narendranath Epperla, Paolo Caimi, Timothy Voorhees

“…Abstract: Chimeric antigen receptor T-cell (CAR-T) therapies are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) can affect a significant number of patients. …”
Get full text

CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist? by Marie José Kersten, Maria Theresa Kuipers

Get full text

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas by Gohar S. Manzar, Chelsea C. Pinnix, Stephanie O. Dudzinski, Kathryn E. Marqueen, Elaine E. Cha, Lewis F. Nasr, Alison K. Yoder, Michael K. Rooney, Paolo Strati, Sairah Ahmed, Chijioke Nze, Ranjit Nair, Luis E. Fayad, Michael Wang, Loretta J. Nastoupil, Jason R. Westin, Christopher R. Flowers, Sattva S. Neelapu, Jillian R. Gunther, Bouthaina S. Dabaja, Susan Y. Wu, Penny Q. Fang

“…BackgroundSelect patients with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T cell therapy (CAR-T). Here, we examined patient and treatment factors associated with outcomes and patterns of failure after bRT and CAR-T.MethodsWe retrospectively reviewed adults with diffuse large B-cell lymphoma (DLBCL) who received bRT prior to axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel between 11/2017-4/2023. …”
Get full text

The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis by Jile Liu, Yuxin An, Rui Sun, Xiaomei Zhang, Shujing Guo, Xuejin Gao, Mingfeng Zhao

Subjects: Get full text

Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies by Max Topp, Michael Hudecek, Hermann Einsele, Imad Maatouk, Leo Rasche, Johannes Duell, Anna Fleischer, Sophia Kurth, Patrick-Pascal Strunz, Julia Mersi, Carmen Sanges

Get full text

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment by Rahul Navab, Pragyat Futela, Verkha Kumari, Jayesh Valecha, Ramansh Bandhu Gupta, Rohit Jain

Get full text

SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report by Hongyan Liu, Colleen Callahan, Shannon L Maude, Kevin Owen McNerney, Rebecca M Richards, Paibel Aguayo-Hiraldo, Friso G Calkoen, Julie-An Talano, Amy Moskop, Adriana Balduzzi, Jennifer Krajewski, Hema Dave, Anant Vatsayan, Yimei Li, Kara Lynn Davis

Get full text

Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults by Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Coffey, Arend von Stackelberg, Semjon Willier, Brigitte Strahm, Christina Peters, Tobias Feuchtinger

“…Abstract Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. …”
Get full text

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design by Haiying Qin, Nirali N Shah, Terry J Fry, Lila Yang, John A Chukinas, Samiksha Tarun, Marie Pouzolles, Christopher D Chien, Lisa M Niswander, Anthony R Welch, Sarah K Tasian, Naomi A Taylor

Get full text

The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy by Jinlan Long, Shufeng Xie, Wenjie Zhang, Weiyu Dou, Yixin Wang, Ruiheng Wang, Han Liu, Zhenshu Xu

Get full text

Peer Review of “Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Recurrent Glioblastoma: An Augmented Meta-Analysis of Phase 1 Clinical Trials (Preprint)” by Vanessa Fairhurst, Randa Salah Gomaa Mahmoud, Toba Olatoye, Sylvester Sakilay

Get full text